Skip to content

K-Stock Briefing

https://kstockbriefing.com

  • About Us
  • News
    • News
  • IR Room
  • RESEARCH
  • Disclosures
    • Semiconductors
    • Bio & Healthcare
    • Defense
    • Shipbuilding
  • Toggle search form

[Disclosure] Celltrion (068270) Decides to Convene AGM on March 25, 2025; Proposes Re-election of Chairman Seo Jung-jin as Inside Director

Posted on February 25, 2025July 16, 2026 By K-STOCK Editor No Comments on [Disclosure] Celltrion (068270) Decides to Convene AGM on March 25, 2025; Proposes Re-election of Chairman Seo Jung-jin as Inside Director

Source: Financial Supervisory Service Dart System / 2025-02-25

Disclosure Type: Decision to Convene General Meeting of Shareholders

💡 3-Second Summary

Celltrion has resolved to hold its 34th Annual General Meeting of Shareholders on March 25, 2025, submitting agendas including the approval of financial statements, reduction of capital reserve, and the re-election of Chairman Seo Jung-jin to the board.

📊 1. [Key Disclosure Content & Major Figures Summary]

  • AGM Schedule & Venue:
    • Type: Annual General Meeting of Shareholders (AGM)
    • Date & Time: March 25, 2025 at 10:00 AM (KST)
    • Location: 2nd Floor, Songdo Convensia, 123 Central-ro, Yeonsu-gu, Incheon, South Korea
  • Key Agendas to be Presented:
    • Reporting Items: Audit Report and Business Report for the 34th Fiscal Year, Report on the Operational Status of the Internal Accounting Control System (Consolidated and Separate) for the 34th Fiscal Year
    • Proposed Agendas:
      • Agenda 1: Approval of Financial Statements for the 34th Fiscal Year
      • Agenda 2: Approval of Reduction of Capital Reserve
      • Agenda 3: Election of Directors (Re-election of Inside Director candidate Seo Jung-jin)
      • Agenda 4: Approval of Limit on Director Compensation
      • Agenda 5: Amendment to Executive Retirement Pay Regulations
  • Details on Director Nominee:
    • Nominee: Seo Jung-jin (Born October 1957)
    • New Appointment: No (Re-election for a 2-year term)
    • Primary Experience: Current Board Chairman and Chairman of Celltrion Co., Ltd.
  • Board Resolution Status:
    • Resolution Date: February 25, 2025 (8 outside directors present, 0 absent)
    • Note: The company’s audit committee is composed entirely of outside directors.

📈 2. [Expert Perspective: What This Means for Investors]

  • Establishment of Regulatory Timeline: The filing establishes the exact timeline (March 25, 2025) and location for the closing of the 34th fiscal year. This initiates the formal administrative procedure for the presentation of audited figures and corporate governance voting.
  • Proposed Board Continuity: The agenda includes the nomination of current Chairman Seo Jung-jin for re-election as an inside director for a two-year term. This represents a planned continuation of the current executive leadership, contingent upon shareholder approval at the general meeting.
  • Formal Voting on Financial & Administrative Matters: Agendas regarding the approval of financial statements, reduction of capital reserves, director compensation limits, and pension amendments will be put to a vote. Shareholders must participate to determine if these initiatives will be executed as proposed.

📝 Editor’s Comment (by K-STOCK Editor)

Celltrion has issued a formal notification to shareholders regarding the convocation of its 34th Annual General Meeting. This filing serves as the official mechanism to outline the reporting requirements and board nominations scheduled for voter consideration.

The primary check point for investors moving forward is the official voting outcomes of the general meeting scheduled on March 25, 2025. Investors should monitor the subsequent disclosure to verify whether all proposed agendas, from Agenda 1 through Agenda 5, including the re-election of the inside director, are passed without modifications.

Furthermore, because the meeting involves decisions on financial allocations such as capital reserve modifications and regulatory compensation rules, checking the final approved terms against the initial proposals in the follow-up regulatory filing is necessary to confirm their execution.

📢 Disclaimer & Sources

Source: This content was structured and newly generated based on official disclosure data submitted to the Financial Supervisory Service (DART) of South Korea.

Investment Risk Notice: This information is provided for informational and linguistic reference purposes only. Under no circumstances does it constitute financial advice or a recommendation to buy or sell any specific stock. All investment decisions and financial responsibilities rest solely with the investor.

Inquiries: For compliance queries or copyright requests, please contact ksb220805@gmail.com.

🐂
BULLS
VS
🐻
BEARS

🔥 Bulls vs Bears, drop your analysis in the comments!

Disclosures, Bio & Healthcare

Post navigation

Previous Post: [Disclosure] LEENO Industrial (058470) Convokes AGM to Approve ₩3,000 Dividend & Stock Split… Hopes High for Thirst-Quenching Liquidity Boost
Next Post: [Disclosure] Celltrion (068270) Logs Preliminary Separate Q4 Revenue of KRW 1.06T, Increasing 235.96% YoY

Related Posts

[Disclosure] Samsung Electro-Mechanics (009150) Confirms AGM for March 20; Nominates MLCC Expert Jaeyeol Choi as Inside Director Semiconductors
[Disclosure] SK Square (402340) Designated as ‘Investment Caution’ Stock Due to High Concentration of Trading in a Few Foreign Accounts Following 16.45% Surge Semiconductors
[Disclosure] Celltrion Secures European CHMP Recommendation for Marketing Authorization of CT-P42 (068270) Disclosures
[Disclosure] Hanwha Aerospace (012450) Submits Consolidated Audit Report for 48th Fiscal Year… Receives ‘Unqualified’ Audit Opinion with Net Income of Approx. KRW 2.5T Disclosures
[Disclosure] Hanwha Aerospace (012450) Announces Mid-to-Long-Term Investment Strategy (Planning Total Investment of Approx. KRW 28T in Space Launch Vehicles & Defense AI) Disclosures
[Disclosure] Celltrion Obtains South Korean MFDS Approval for Stoboclo and Osenvelt (068270) Disclosures

Leave a Reply Cancel reply

You must be logged in to post a comment.

  • [Disclosure] Alteogen (196170) Establishes August 6 as Record Date for Bonus Issue Share AllotmentJuly 16, 2026
  • [Disclosure] Alteogen (196170) Announces Trading Suspension and Resumption Schedule for Stock Futures and OptionsJuly 16, 2026
  • [Disclosure] Alteogen (196170) Temporarily Suspends Plans for Relisting on the KOSPI MarketJuly 16, 2026
  • [Disclosure] Alteogen (196170) Announces Temporary Trading Suspension on July 16 Due to Bonus Issue DecisionJuly 16, 2026
  • [Disclosure] Alteogen (196170) Decides on Bonus Issue of 0.3 Shares per 1 Common and Preferred ShareJuly 16, 2026

Copyright © 2026 K-Stock Briefing.

Powered by PressBook Grid Dark theme